Keyword: Shire

As Japanese pharma Takeda keeps divesting assets, its new big biotech buy Shire keeps divesting research executives.

After getting off a $75 million IPO last year, AstraZeneca’s antibiotics spinout Entasis has hired a former Shire executive to lead its R&D programs.

Takeda’s cytomegalovirus drug beat Roche’s Valcyte at clearing the virus in patients who had undergone an organ transplant or stem cell transplant.

After shepherding the injected HAE med Firazyr through approval, Jochen Knolle is working on an oral treatment for the disease.

Shire R&D chief jumps ship to Ironwood spinout; Daiichi taps new CEO; and Kymab nabs new CEO from Merck KGaA.

With $225 million from TPG Capital and Vida Ventures and $10 million from its founders and board members, AskBio will ramp up clinical trials and manufacturing.

Rare disease biotech Cyclerion has poached Shire’s ex-head of R&D, Andy Busch, Ph.D., as its new chief innovation officer, less than 18 months after he joined the company from his long stint at Bayer.

Attune Pharmaceuticals raised $23 million in series B financing to push its oral drug for hereditary angioedema through phase 2.